Agreement Set to Expand BUZZ BOMB™ Distribution Across Natural, Specialty, and Mass Merchandiser Channels
ESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John...
ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health...
Convenient Size at the Convenience Store
Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication.
BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.
Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed
ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company...
New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®.
New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform